Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.

Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leuk Lymphoma. 2018 06; 59(6):1338-1347.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Chromosome Aberrations
Chromosomes, Human, Pair 17
Cyclophosphamide
DNA Mutational Analysis
Female
Humans
Immunophenotyping
In Situ Hybridization, Fluorescence
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Neoplasm Staging
Neoplasm, Residual
Rituximab
Survival Analysis
Treatment Outcome
Vidarabine

authors with profiles

Michael Joseph O'Dwyer